Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Debt to Equity (2017 - 2024)

Organogenesis Holdings has reported Debt to Equity over the past 8 years, most recently at $0.22 for Q3 2024.

  • Quarterly results put Debt to Equity at $0.22 for Q3 2024, down 8.67% from a year ago — trailing twelve months through Sep 2024 was $0.22 (down 8.67% YoY), and the annual figure for FY2023 was $0.24, down 10.78%.
  • Debt to Equity for Q3 2024 was $0.22 at Organogenesis Holdings, down from $0.24 in the prior quarter.
  • Over the last five years, Debt to Equity for ORGO hit a ceiling of $1.45 in Q2 2020 and a floor of $0.19 in Q2 2021.
  • Median Debt to Equity over the past 5 years was $0.27 (2022), compared with a mean of $0.36.
  • Peak annual rise in Debt to Equity hit 61.8% in 2021, while the deepest fall reached 87.13% in 2021.
  • Organogenesis Holdings' Debt to Equity stood at $0.19 in 2020, then skyrocketed by 61.8% to $0.3 in 2021, then fell by 12.45% to $0.27 in 2022, then decreased by 10.78% to $0.24 in 2023, then decreased by 6.17% to $0.22 in 2024.
  • The last three reported values for Debt to Equity were $0.22 (Q3 2024), $0.24 (Q2 2024), and $0.23 (Q1 2024) per Business Quant data.